Insights into the relationship between serum uric acid and pulmonary hypertension (Review)
- Authors:
- Yu Zhou
- Meihong Chen
- Jing Zheng
- Xiaorong Shui
- Yuan He
- Hui Luo
- Wei Lei
-
Affiliations: Guangdong Provincial Engineering Technology Research Center for Molecular Diagnosis and Innovative Drugs Translation of Cardiopulmonary Vascular Diseases, University Joint Laboratory of Guangdong and Macao on Molecular Targets and Intervention of Cardiovascular Diseases, Zhanjiang, Guangdong 524001, P.R. China, Department of Obstetrics and Gynecology, University of Wisconsin, Madison, WI 53715, USA, Laboratory of Vascular Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China, Southern Marine Science and Engineering Guangdong Laboratory, The Marine Biomedical Research Institute, Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China - Published online on: November 21, 2023 https://doi.org/10.3892/mmr.2023.13133
- Article Number: 10
-
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, Jing ZC and Gibbs JS: A global view of pulmonary hypertension. Lancet Respir Med. 4:306–322. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Beshay S, Sahay S and Humbert M: Evaluation and management of pulmonary arterial hypertension. Respir Med. 171:1060992020. View Article : Google Scholar : PubMed/NCBI | |
|
Morrell NW, Aldred MA, Chung WK, Elliott CG, Nichols WC, Soubrier F, Trembath RC and Loyd JE: Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 53:18018992019. View Article : Google Scholar : PubMed/NCBI | |
|
Levine DJ: Pulmonary arterial hypertension: Updates in epidemiology and evaluation of patients. Am J Manag Care. 27 (3 Suppl):S35–S41. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, et al: Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 107:216–223. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Girerd B, Montani D, Eyries M, Yaici A, Sztrymf B, Coulet F, Sitbon O, Simonneau G, Soubrier F and Humbert M: Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res. 11:732010. View Article : Google Scholar : PubMed/NCBI | |
|
Ventetuolo CE, Praestgaard A, Palevsky HI, Klinger JR, Halpern SD and Kawut SM: Sex and haemodynamics in pulmonary arterial hypertension. Eur Respir J. 43:523–530. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, Wang ZW, Cheng XS, Xu B, Hu SS, et al: Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 132:373–379. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Sun M, Jiang X, Zhang R, Zhao Q, Wang Y, Sun K, Wang X, Peng F, Zheng L, et al: Comparison of clinical characteristics and survival on patients with idiopathic pulmonary arterial hypertension and familial pulmonary arterial hypertension during conventional therapy era and targeted therapy era. Zhonghua Xin Xue Guan Bing Za Zhi. 42:465–468. 2014.(In Chinese). PubMed/NCBI | |
|
Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ and Rabinovitch M: Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation. 115:1275–1284. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, Rabinovitch M and Doyle RL: Insulin resistance in pulmonary arterial hypertension. Eur Respir J. 33:318–324. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fessel JP, Hamid R, Wittmann BM, Robinson LJ, Blackwell T, Tada Y, Tanabe N, Tatsumi K, Hemnes AR and West JD: Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Pulm Circ. 2:201–213. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zare E, Kafshbani P, Chenaghlou M, Noori M, Ghaemmaghami Z, Amin A, Taghavi S and Naderi N: Prognostic significance of insulin resistance in pulmonary hypertension. ESC Heart Fail. 9:318–326. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Feig DI, Kang DH and Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med. 359:1811–1821. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gagliardi AC, Miname MH and Santos RD: Uric acid: A marker of increased cardiovascular risk. Atherosclerosis. 202:11–17. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Borghi C and Cicero AFG: Serum uric acid and acute coronary syndrome: Is there a role for functional markers of residual cardiovascular risk. Int J Cardiol. 250:62–63. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ndrepepa G: Uric acid and cardiovascular disease. Clin Chim Acta. 484:150–163. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Krishnan E, Kwoh CK, Schumacher HR and Kuller L: Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 49:298–303. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Brodov Y, Behar S, Boyko V and Chouraqui P: Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study). Am J Cardiol. 106:1717–1720. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Galassi FM and Borghi C: A brief history of uric acid: From gout to cardiovascular risk factor. Eur J Intern Med. 26:3732015. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Hu X, Fan Y, Li K, Zhang X, Hou W and Tang Z: Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep. 6:195202016. View Article : Google Scholar : PubMed/NCBI | |
|
Kuwabara M, Niwa K, Nishihara S, Nishi Y, Takahashi O, Kario K, Yamamoto K, Yamashita T and Hisatome I: Hyperuricemia is an independent competing risk factor for atrial fibrillation. Int J Cardiol. 231:137–142. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, Nakagawa T, Madero M, Feig DI, Borghi C, Piani F, Cara-Fuentes G, Bjornstad P, et al: Uric acid and hypertension: An update with recommendations. Am J Hypertens. 33:583–594. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Si K, Wei C, Xu L, Zhou Y, Lv W, Dong B, Wang Z, Huang Y, Wang Y and Chen Y: Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications. Front Endocrinol (Lausanne). 12:7708152021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Hou Y, Wang X, Li Z, Wang X, Li H, Shang L, Zhou J and Zhang Y, Ren M and Zhang Y: Relationship between serum uric acid levels and different types of atrial fibrillation: An updated meta-analysis. Nutr Metab Cardiovasc Dis. 31:2756–2765. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Gomes MT, Bai Y, Potje SR, Zhang L, Lockett AD and Machado RF: Signal transduction during metabolic and inflammatory reprogramming in pulmonary vascular remodeling. Int J Mol Sci. 23:24102022. View Article : Google Scholar : PubMed/NCBI | |
|
Perera FP, Rauh V, Whyatt RM, Tang D, Tsai WY, Bernert JT, Tu YH, Andrews H, Barr DB, Camann DE, et al: A summary of recent findings on birth outcomes and developmental effects of prenatal ETS, PAH, and pesticide exposures. Neurotoxicology. 26:573–587. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, et al: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 43:3618–3731. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, et al: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 61:22008792023. View Article : Google Scholar : PubMed/NCBI | |
|
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 46:903–975. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al: 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 37:67–119. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 54 (1 Suppl):S43–S54. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Gelzinis TA: Pulmonary Hypertension in 2021: Part I-Definition, Classification, Pathophysiology, and Presentation. J Cardiothorac Vasc Anesth. 36:1552–1564. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Badesch DB, Champion HC, Gomez Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ and Torbicki A: Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 54 (1 Suppl):S55–S66. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Assad TR and Hemnes AR: Metabolic dysfunction in pulmonary arterial hypertension. Curr Hypertens Rep. 17:202015. View Article : Google Scholar : PubMed/NCBI | |
|
Satoh T, Wang L, Espinosa-Diez C, Wang B, Hahn SA, Noda K, Rochon ER, Dent MR, Levine AR, Baust JJ, et al: Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent downregulation of soluble guanylate cyclase and contributes to exercise-induced pulmonary hypertension in heart failure with preserved ejection fraction. Circulation. 144:615–637. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Nicolls MR and Voelkel NF: Hypoxia and the lung: Beyond hypoxic vasoconstriction. Antioxid Redox Signal. 9:741–743. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Langleben D, Orfanos SE, Giovinazzo M, Hirsch A, Baron M, Senécal JL, Armaganidis A and Catravas JD: Pulmonary capillary endothelial metabolic dysfunction: Severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis Rheum. 58:1156–1164. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jones PL, Cowan KN and Rabinovitch M: Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease. Am J Pathol. 150:1349–1360. 1997.PubMed/NCBI | |
|
Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD and Tuder RM: Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 186:261–272. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe T, Ishikawa M, Abe K, Ishikawa T, Imakiire S, Masaki K, Hosokawa K, Fukuuchi T, Kaneko K, Ohtsubo T, et al: Increased Lung Uric Acid Deteriorates Pulmonary Arterial Hypertension. J Am Heart Assoc. 10:e0227122021. View Article : Google Scholar : PubMed/NCBI | |
|
Lippi G, Montagnana M, Franchini M, Favaloro EJ and Targher G: The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta. 392:1–7. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yamaoka T and Itakura M: Metabolism of purine nucleotides and the production of uric acid. Nihon Rinsho. 54:3188–3194. 1996.(In Japanese). PubMed/NCBI | |
|
El Ridi R and Tallima H: Physiological functions and pathogenic potential of uric acid: A review. J Adv Res. 8:487–493. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Benn CL, Dua P, Gurrell R, Loudon P, Pike A, Storer RI and Vangjeli C: Physiology of hyperuricemia and urate-lowering treatments. Front Med (Lausanne). 5:1602018. View Article : Google Scholar : PubMed/NCBI | |
|
Maiuolo J, Oppedisano F, Gratteri S, Muscoli C and Mollace V: Regulation of uric acid metabolism and excretion. Int J Cardiol. 213:8–14. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chaudhary K, Malhotra K, Sowers J and Aroor A: Uric Acid-key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med. 3:208–220. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gherghina ME, Peride I, Tiglis M, Neagu TP, Niculae A and Checherita IA: Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment. Int J Mol Sci. 23:31882022. View Article : Google Scholar : PubMed/NCBI | |
|
Sánchez-Lozada LG, Nakagawa T, Kang DH, Feig DI, Franco M, Johnson RJ and Herrera-Acosta J: Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens. 15:30–33. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Chen C, Lü JM and Yao Q: Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview. Med Sci Monit. 22:2501–2512. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Furuhashi M: New insights into purine metabolism in metabolic diseases: Role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab. 319:E827–E834. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shima Y, Teruya K and Ohta H: Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese. Life Sci. 79:2234–2237. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Caulfield MJ, Munroe PB, O'Neill D, Witkowska K, Charchar FJ, Doblado M, Evans S, Eyheramendy S, Onipinla A, Howard P, et al: SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 5:e1972008. View Article : Google Scholar : PubMed/NCBI | |
|
Wright AF, Rudan I, Hastie ND and Campbell H: A ‘complexity’ of urate transporters. Kidney Int. 78:446–452. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ma Q, Fang L, Su R, Ma L, Xie G and Cheng Y: Uric acid stones, clinical manifestations and therapeutic considerations. Postgrad Med J. 94:458–462. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lipkowitz MS: Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 14:179–188. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, Shimizu T, Yamanashi Y, Kasuga H, Nakashima H, Nakamura T, et al: Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 3:7642012. View Article : Google Scholar : PubMed/NCBI | |
|
Eckenstaler R and Benndorf RA: The Role of ABCG2 in the pathogenesis of primary hyperuricemia and Gout-An Update. Int J Mol Sci. 22:66782021. View Article : Google Scholar : PubMed/NCBI | |
|
Homolya L: Medically Important Alterations in Transport Function and Trafficking of ABCG2. Int J Mol Sci. 22:27862021. View Article : Google Scholar : PubMed/NCBI | |
|
Ohashi Y, Toyoda M, Saito N, Koizumi M, Kanai G, Komaba H, Kimura M, Wada T, Takahashi H, Takahashi Y, et al: Evaluation of ABCG2-mediated extra-renal urate excretion in hemodialysis patients. Sci Rep. 13:932023. View Article : Google Scholar : PubMed/NCBI | |
|
Su J, Wei Y, Liu M, Liu T, Li J, Ji Y and Liang J: Anti-hyperuricemic and nephroprotective effects of Rhizoma Dioscoreae septemlobae extracts and its main component dioscin via regulation of mOAT1, mURAT1 and mOCT2 in hypertensive mice. Arch Pharm Res. 37:1336–1344. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wu XH, Zhang J, Wang SQ, Yang VC, Anderson S and Zhang YW: Riparoside B and timosaponin J, two steroidal glycosides from Smilax riparia, resist to hyperuricemia based on URAT1 in hyperuricemic mice. Phytomedicine. 21:1196–1201. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nath SD, Voruganti VS, Arar NH, Thameem F, Lopez-Alvarenga JC, Bauer R, Blangero J, MacCluer JW, Comuzzie AG and Abboud HE: Genome scan for determinants of serum uric acid variability. J Am Soc Nephrol. 18:3156–3163. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Anzai N, Jutabha P, Amonpatumrat-Takahashi S and Sakurai H: Recent advances in renal urate transport: Characterization of candidate transporters indicated by genome-wide association studies. Clin Exp Nephrol. 16:89–95. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Dehghan A, van Hoek M, Sijbrands EJ, Hofman A and Witteman JC: High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 31:361–362. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Okada Y, Sim X, Go MJ, Wu JY, Gu D, Takeuchi F, Takahashi A, Maeda S, Tsunoda T, Chen P, et al: Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. Nat Genet. 44:904–909. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Major TJ, Dalbeth N, Stahl EA and Merriman TR: An update on the genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 14:341–353. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sautin YY and Johnson RJ: Uric acid: The oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 27:608–619. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jakše B, Jakše B, Pajek M and Pajek J: Uric acid and plant-based nutrition. Nutrients. 11:17362019. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H, Yang Q, Johnson RJ and Yu X: Clinical outcome of hyperuricemia in IgA nephropathy: A retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 35:153–160. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Joosten LAB, Crişan TO, Bjornstad P and Johnson RJ: Asymptomatic hyperuricaemia: A silent activator of the innate immune system. Nat Rev Rheumatol. 16:75–86. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D and Lambers Heerspink HJ: Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 58:2–7. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ames BN, Cathcart R, Schwiers E and Hochstein P: Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci USA. 78:6858–6862. 1981. View Article : Google Scholar : PubMed/NCBI | |
|
Zou H, Wang H, Liu T, Li X, Zhu X and Wang Z: Protective role of α-lipoic acid in hyperuricemia-induced endothelial dysfunction. Exp Ther Med. 13:3047–3054. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Shi Y, Evans JE and Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 425:516–521. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Netea MG, Kullberg BJ, Blok WL, Netea RT and van der Meer JW: The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood. 89:577–582. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Bagnati M, Perugini C, Cau C, Bordone R, Albano E and Bellomo G: When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: A study using uric acid. Biochem J. 340((Pt 1)): 143–152. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Kang DH, Park SK, Lee IK and Johnson RJ: Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 16:3553–3562. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Patterson RA, Horsley ET and Leake DS: Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: Important role of uric acid. J Lipid Res. 44:512–521. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Samocha-Bonet D, Lichtenberg D and Pinchuk I: Kinetic studies of copper-induced oxidation of urate, ascorbate and their mixtures. J Inorg Biochem. 99:1963–1972. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Sautin YY, Nakagawa T, Zharikov S and Johnson RJ: Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 293:C584–C596. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang JX, Zhang YP, Wu QN and Chen B: Uric acid induces oxidative stress via an activation of the renin-angiotensin system in 3T3-L1 adipocytes. Endocrine. 48:135–142. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang JG, Staessen JA, Fagard RH, Birkenhäger WH, Gong L and Liu L: Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension. 37:1069–1074. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Kuzkaya N, Weissmann N, Harrison DG and Dikalov S: Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: Implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol. 70:343–354. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, Ohya Y and Takishita S: Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res. 27:835–841. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Morris CR, Kuypers FA, Kato GJ, Lavrisha L, Larkin S, Singer T and Vichinsky EP: Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci. 1054:481–485. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Castro O, Hoque M and Brown BD: Pulmonary hypertension in sickle cell disease: Cardiac catheterization results and survival. Blood. 101:1257–1261. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Verresen D, De Backer W, Van Meerbeeck J, Neetens I, Van Marck E and Vermeire P: Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship. Eur Respir J. 4:629–631. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Heller PG, Grinberg AR, Lencioni M, Molina MM and Roncoroni AJ: Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria. Chest. 102:642–643. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Devalet B, Mullier F, Chatelain B, Dogné JM and Chatelain C: Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: A review. Eur J Haematol. 95:190–198. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tofovic SP, Jackson EK and Rafikova O: Adenosine deaminase-adenosine pathway in hemolysis-associated pulmonary hypertension. Med Hypotheses. 72:713–719. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Cerqueira BA, Boas WV, Zanette AD, Reis MG and Goncalves MS: Increased concentrations of IL-18 and uric acid in sickle cell anemia: Contribution of hemolysis, endothelial activation and the inflammasome. Cytokine. 56:471–476. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Robbins IM, Newman JH, Johnson RF, Hemnes AR, Fremont RD, Piana RN, Zhao DX and Byrne DW: Association of the metabolic syndrome with pulmonary venous hypertension. Chest. 136:31–36. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Quiñones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D and Ferrannini E: Effect of insulin on uric acid excretion in humans. Am J Physiol. 268((1 Pt 1)): E1–E5. 1995.PubMed/NCBI | |
|
Gashouta MA, Humbert M and Hassoun PM: Update in systemic sclerosis-associated pulmonary arterial hypertension. Presse Med. 43((10 Pt 2)): e293–e304. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kherbeck N, Tamby MC, Bussone G, Dib H, Perros F, Humbert M and Mouthon L: The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin Rev Allergy Immunol. 44:31–38. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ferreira NS, Tostes RC, Paradis P and Schiffrin EL: Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens. 34:15–27. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, Yamagishi M, Kunieda T and Miyatake K: Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med. 160:487–492. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Editorial. Major changes made by Criteria Committee of the New York Heart Association. Circulation. 49:3901974. View Article : Google Scholar : PubMed/NCBI | |
|
Voelkel MA, Wynne KM, Badesch DB, Groves BM and Voelkel NF: Hyperuricemia in severe pulmonary hypertension. Chest. 117:19–24. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Li ZN, He JG, Liu ZH, Gu Q, Ni XH, Cheng XS and Xiong CM: Relationship between serum uric acid levels and patient conditions and prognosis in idiopathic pulmonary arterial hypertension. Zhonghua Yi Xue Za Zhi. 92:3261–3264. 2012.(In Chinese). PubMed/NCBI | |
|
Zhang CY, Ma LL and &Wang LX: Relationship between serum uric acid levels and ventricular function in patients with idiopathic pulmonary hypertension. Exp Clin Cardiol. 18:e37–3e9. 2013.PubMed/NCBI | |
|
Seyyedi SR, Malekmohammad M, Chitsazan M, Behzadnia N, Sadr M, Hashemian SM and Sharif-Kashani B: Relationship between Serum Uric Acid Levels and the Severity of Pulmonary Hypertension. Tanaffos. 16:283–288. 2017.PubMed/NCBI | |
|
Yan L, Huang Z, Zhao Z, Zhao Q, Tang Y, Zhang Y, Li X, Duan A, Luo Q and Liu Z: The Prognostic Impact of Serum Uric Acid on Disease Severity and 5-Year mortality in patients with idiopathic pulmonary artery hypertension. Front Med (Lausanne). 9:8054152022. View Article : Google Scholar : PubMed/NCBI | |
|
Dhaun N, Vachiery JL, Benza RL, Naeije R, Hwang LJ, Liu X, Teal S and Webb DJ: Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: Clinical associations. J Heart Lung Transplant. 33:521–527. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Dimitroulas T, Giannakoulas G, Dimitroula H, Sfetsios T, Parcharidou D, Karvounis H and Settas L: Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: A pilot study. Rheumatol Int. 31:263–267. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Denton CP: Systemic sclerosis: From pathogenesis to targeted therapy. Clin Exp Rheumatol. 33 (4 Suppl 92):S3–S7. 2015.PubMed/NCBI | |
|
Gigante A, Barbano B, Barilaro G, Quarta S, Gasperini ML, Di Mario F, Romaniello A, Amoroso A, Cianci R and Rosato E: Serum uric acid as a marker of microvascular damage in systemic sclerosis patients. Microvasc Res. 106:39–43. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pagkopoulou E, Soulaidopoulos S, Triantafyllidou E, Malliari A, Kitas GD, Garyfallos A and Dimitroulas T: Association Between Uric Acid and Worsening Peripheral Microangiopathy in Systemic Sclerosis. Front Med (Lausanne). 8:8069252021. View Article : Google Scholar : PubMed/NCBI | |
|
Aghdashi M, Behnemoon M, Mahmoodi Rad J and Rabiepour M: Evaluation of serum uric acid level in systemic lupus erythematosus patients with normal and high pulmonary arterial hypertension. Biomedicine (Taipei). 8:162018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim KJ, Baek IW, Park YJ, Yoon CH, Kim WU and Cho CS: High levels of uric acid in systemic lupus erythematosus is associated with pulmonary hypertension. Int J Rheum Dis. 18:524–532. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Castillo-Martínez D, Marroquín-Fabián E, Lozada-Navarro AC, Mora-Ramírez M, Juárez M, Sánchez-Muñoz F, Vargas-Barrón J, Sandoval J and Amezcua-Guerra LM: Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus: A seven-year follow-up study. Lupus. 25:61–66. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Njaman W, Iesaki T, Iwama Y, Takasaki Y and Daida H: Serum uric Acid as a prognostic predictor in pulmonary arterial hypertension with connective tissue disease. Int Heart J. 48:523–532. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Luo DL, Zhang CJ, Huang YG, Huang T and Li HZ: Serum uric acid is associated with disease severity and an important predictor for clinical outcome in patients with pulmonary hypertension. Zhonghua Xin Xue Guan Bing Za Zhi. 45:496–500. 2017.(In Chinese). PubMed/NCBI | |
|
Simpson CE, Damico RL, Hummers L, Khair RM, Kolb TM, Hassoun PM and Mathai SC: Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. Pulm Circ. 9:20458940198594772019. View Article : Google Scholar : PubMed/NCBI | |
|
Uk Kang T, Park KY, Kim HJ, Ahn HS, Yim SY and Jun JB: Association of hyperuricemia and pulmonary hypertension: A systematic review and meta-analysis. Mod Rheumatol. 29:1031–1041. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hong JW, Noh JH and Kim DJ: Association between serum uric acid and spirometric pulmonary function in Korean adults: The 2016 Korea National Health and Nutrition Examination Survey. PLoS One. 15:e02409872020. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J and Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease. Hypertension. 41:1183–1190. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S and Johnson RJ: Hyperuricemia induces endothelial dysfunction. Kidney Int. 67:1739–1742. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
O'Riordan E, Chen J, Brodsky SV, Smirnova I, Li H and Goligorsky MS: Endothelial cell dysfunction: The syndrome in making. Kidney Int. 67:1654–1658. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
van Thiel BS, van der Pluijm I, te Riet L, Essers J and Danser AH: The renin-angiotensin system and its involvement in vascular disease. Eur J Pharmacol. 763((Pt A)): 3–14. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Podkowińska A and Formanowicz D: Chronic kidney disease as oxidative stress- and inflammatory-mediated cardiovascular disease. Antioxidants (Basel). 9:7522020. View Article : Google Scholar : PubMed/NCBI | |
|
Rao GN, Corson MA and Berk BC: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem. 266:8604–8608. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B and Johnson RJ: The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 99:759–766. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Potente M, Gerhardt H and Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell. 146:873–887. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Eelen G, Treps L, Li X and Carmeliet P: Basic and therapeutic aspects of angiogenesis updated. Circ Res. 127:310–329. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Krüger-Genge A, Blocki A, Franke RP and Jung F: Vascular endothelial cell biology: An update. Int J Mol Sci. 20:44112019. View Article : Google Scholar : PubMed/NCBI | |
|
Dai Z, Zhu MM, Peng Y, Jin H, Machireddy N, Qian Z, Zhang X and Zhao YY: Endothelial and smooth muscle cell interaction via FoxM1 signaling mediates vascular remodeling and pulmonary hypertension. Am J Respir Crit Care Med. 198:788–802. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Evans CE, Cober ND, Dai Z, Stewart DJ and Zhao YY: Endothelial cells in the pathogenesis of pulmonary arterial hypertension. Eur Respir J. 58:20039572021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu B, Peng Y, Yi D, Machireddy N, Dong D, Ramirez K, Dai J, Vanderpool R, Zhu MM, Dai Z and Zhao YY: Endothelial PHD2 deficiency induces nitrative stress via suppression of caveolin-1 in pulmonary hypertension. Eur Respir J. 60:21026432022. View Article : Google Scholar : PubMed/NCBI | |
|
Zharikov SI, Swenson ER, Lanaspa M, Block ER, Patel JM and Johnson RJ: Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension? Med Hypotheses. 74:1069–1074. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Komaszyło K, Zalewska R, Mariak Z and Wiśniewska RJ: Biosynthesis of nitric oxide and its function in organism. Klin Oczna. 108:99–102. 2006.(In Polish). PubMed/NCBI | |
|
Gersch C, Palii SP, Kim KM, Angerhofer A, Johnson RJ and Henderson GN: Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids. 27:967–978. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Förstermann U: Janus-faced role of endothelial NO synthase in vascular disease: Uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem. 387:1521–1533. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Mishima M, Hamada T, Maharani N, Ikeda N, Onohara T, Notsu T, Ninomiya H, Miyazaki S, Mizuta E, Sugihara S, et al: Effects of Uric Acid on the NO Production of HUVECs and its Restoration by Urate Lowering Agents. Drug Res (Stuttg). 66:270–274. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li P, Zhang L, Zhang M, Zhou C and Lin N: Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: A mechanism for uric acid-induced endothelial dysfunction. Int J Mol Med. 37:989–997. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Choi YJ, Yoon Y, Lee KY, Hien TT, Kang KW, Kim KC, Lee J, Lee MY, Lee SM, Kang DH and Lee BH: Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. FASEB J. 28:3197–3204. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bahadoran Z, Mirmiran P, Kashfi K and Ghasemi A: Hyperuricemia-induced endothelial insulin resistance: The nitric oxide connection. Pflugers Arch. 474:83–98. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Roy D, Perreault M and Marette A: Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am J Physiol. 274:E692–E699. 1998.PubMed/NCBI | |
|
Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J, et al: A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 290:F625–F631. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lee TS, Lu TM, Chen CH, Guo BC and Hsu CP: Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/dimethylarginine dimethylaminotransferase 2 pathway. Redox Biol. 46:1021082021. View Article : Google Scholar : PubMed/NCBI | |
|
Deedwania PC: Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr Diab Rep. 3:289–292. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Yu W and Cheng JD: Uric acid and cardiovascular disease: An update from molecular mechanism to clinical perspective. Front Pharmacol. 11:5826802020. View Article : Google Scholar : PubMed/NCBI | |
|
Lee KS, Kim J, Kwak SN, Lee KS, Lee DK, Ha KS, Won MH, Jeoung D, Lee H, Kwon YG and Kim YM: Functional role of NF-κB in expression of human endothelial nitric oxide synthase. Biochem Biophys Res Commun. 448:101–107. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhen H and Gui F: The role of hyperuricemia on vascular endothelium dysfunction. Biomed Rep. 7:325–330. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Hong Q, Hou K, Wang Y, Wu D and Chen X: High concentration uric acid regulates endothelial function via miR-155. Nan Fang Yi Ke Da Xue Xue Bao. 33:1141–1145. 2013.(In Chinese). PubMed/NCBI | |
|
Zharikov S, Krotova K, Hu H, Baylis C, Johnson RJ, Block ER and Patel J: Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol. 295:C1183–C1190. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hong Q, Qi K, Feng Z, Huang Z, Cui S, Wang L, Fu B, Ding R, Yang J, Chen X and Wu D: Hyperuricemia induces endothelial dysfunction via mitochondrial Na+/Ca2+ exchanger-mediated mitochondrial calcium overload. Cell Calcium. 51:402–410. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sánchez-Lozada LG, Lanaspa MA, Cristóbal-García M, García-Arroyo F, Soto V, Cruz-Robles D, Nakagawa T, Yu MA, Kang DH and Johnson RJ: Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 121:e71–e78. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kang DH, Han L, Ouyang X, Kahn AM, Kanellis J, Li P, Feng L, Nakagawa T, Watanabe S, Hosoyamada M, et al: Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol. 25:425–433. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, Mu W, Endou H and Johnson RJ: Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol. 17:1791–1795. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Oğuz N, Kırça M, Çetin A and Yeşilkaya A: Effect of uric acid on inflammatory COX-2 and ROS pathways in vascular smooth muscle cells. J Recept Signal Transduct Res. 37:500–505. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kırça M, Oğuz N, Çetin A, Uzuner F and Yeşilkaya A: Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ. J Recept Signal Transduct Res. 37:167–173. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bowen-Pope DF, Ross R and Seifert RA: Locally acting growth factors for vascular smooth muscle cells: Endogenous synthesis and release from platelets. Circulation. 72:735–740. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Berk BC: Vascular smooth muscle growth: Autocrine growth mechanisms. Physiol Rev. 81:999–1030. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R and Johnson RJ: A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 13:2888–2897. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, et al: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 282:F991–F997. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M and Johnson RJ: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 40:355–360. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Doğru S, Yaşar E and Yeşilkaya A: Uric acid can enhance MAPK pathway-mediated proliferation in rat primary vascular smooth muscle cells via controlling of mitochondria and caspase-dependent cell death. J Recept Signal Transduct Res. 42:293–301. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH and Aristimuno GG: Serum uric acid in essential hypertension: An indicator of renal vascular involvement. Ann Intern Med. 93:817–821. 1980. View Article : Google Scholar : PubMed/NCBI | |
|
Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L and Johnson RJ: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 41:1287–1293. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Qian F, Liu H and Zhang Z: Elevated Uric Acid Levels Promote Vascular Smooth Muscle Cells (VSMC) Proliferation via an Nod-Like Receptor Protein 3 (NLRP3)-Inflammasome-Dependent Mechanism. Med Sci Monit. 25:8457–8464. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Savale L, Akagi S, Tu L, Cumont A, Thuillet R, Phan C, Le Vely B, Berrebeh N, Huertas A, Jaïs X, et al: Serum and pulmonary uric acid in pulmonary arterial hypertension. Eur Respir J. 58:20003322021. View Article : Google Scholar : PubMed/NCBI | |
|
Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, Scalia R and Eguchi S: Angiotensin II Signal Transduction: An update on mechanisms of physiology and pathophysiology. Physiol Rev. 98:1627–1738. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Satou R, Penrose H and Navar LG: Inflammation as a Regulator of the Renin-Angiotensin System and Blood Pressure. Curr Hypertens Rep. 20:1002018. View Article : Google Scholar : PubMed/NCBI | |
|
Saxena T, Ali AO and Saxena M: Pathophysiology of essential hypertension: An update. Expert Rev Cardiovasc Ther. 16:879–887. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang XD, Liu J, Zhang YC, Wang Y, Wang Y and Ma D: Correlation between the elevated uric acid levels and circulating renin-angiotensin-aldosterone system activation in patients with atrial fibrillation. Cardiovasc Diagn Ther. 11:50–55. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sankrityayan H, Rao PD, Shelke V, Kulkarni YA, Mulay SR and Gaikwad AB: Endoplasmic reticulum stress and renin-angiotensin system crosstalk in endothelial dysfunction. Curr Mol Pharmacol. 16:139–146. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Saito I, Saruta T, Kondo K, Nakamura R, Oguro T, Yamagami K, Ozawa Y and Kato E: Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc. 26:241–247. 1978. View Article : Google Scholar : PubMed/NCBI | |
|
Cappuccio FP, Iacone R and Strazzullo P: Serum uric acid and proximal sodium excretion: An independent association in man (the Olivetti Study). J Hypertens. (Suppl 9):S280–S281. 1991. | |
|
Welch WJ, Wilcox CS and Thomson SC: Nitric oxide and tubuloglomerular feedback. Semin Nephrol. 19:251–262. 1999.PubMed/NCBI | |
|
Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, Hollenberg NK and Fisher ND: Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int. 66:1465–1470. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Feig DI, Kang DH, Nakagawa T, Mazzali M and Johnson RJ: Uric acid and hypertension. Curr Hypertens Rep. 8:111–115. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Brewster UC and Perazella MA: The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease. Am J Med. 116:263–272. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sparks MA, Crowley SD, Gurley SB, Mirotsou M and Coffman TM: Classical Renin-Angiotensin system in kidney physiology. Compr Physiol. 4:1201–1228. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nehme A, Zouein FA, Zayeri ZD and Zibara K: An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology. J Cardiovasc Dev Dis. 6:142019.PubMed/NCBI | |
|
Laghlam D, Jozwiak M and Nguyen LS: Renin-Angiotensin-Aldosterone System and Immunomodulation: A State-of-the-Art Review. Cells. 10:17672021. View Article : Google Scholar : PubMed/NCBI | |
|
Bernstein KE, Khan Z, Giani JF, Cao DY, Bernstein EA and Shen XZ: Angiotensin-converting enzyme in innate and adaptive immunity. Nat Rev Nephrol. 14:325–336. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H and Tuck ML: Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 26:269–275. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yu MA, Sánchez-Lozada LG, Johnson RJ and Kang DH: Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 28:1234–1242. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Basso N and Terragno NA: History about the discovery of the renin-angiotensin system. Hypertension. 38:1246–1249. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Lipworth BJ and Dagg KD: Vasoconstrictor effects of angiotensin II on the pulmonary vascular bed. Chest. 105:1360–1364. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Orte C, Polak JM, Haworth SG, Yacoub MH and Morrell NW: Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol. 192:379–384. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Abraham WT, Raynolds MV, Badesch DB, Wynne KM, Groves BM, Roden RL, Robertson AD, Lowes BD, Zisman LS, Voelkel NF, et al: Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: Increased frequency and association with preserved haemodynamics. J Renin Angiotensin Aldosterone Syst. 4:27–30. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Chung WK, Deng L, Carroll JS, Mallory N, Diamond B, Rosenzweig EB, Barst RJ and Morse JH: Polymorphism in the angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension. J Heart Lung Transplant. 28:373–379. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Berk BC and Rao GN: Angiotensin II-induced vascular smooth muscle cell hypertrophy: PDGF A-chain mediates the increase in cell size. J Cell Physiol. 154:368–380. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Morrell NW, Atochina EN, Morris KG, Danilov SM and Stenmark KR: Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. J Clin Invest. 96:1823–1833. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
de Man FS, Tu L, Handoko ML, Rain S, Ruiter G, François C, Schalij I, Dorfmüller P, Simonneau G, Fadel E, et al: Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med. 186:780–789. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pezzuto B, Badagliacca R, Poscia R, Ghio S, D'Alto M, Vitulo P, Mulè M, Albera C, Volterrani M, Fedele F and Vizza CD: Circulating biomarkers in pulmonary arterial hypertension: Update and future direction. J Heart Lung Transplant. 34:282–305. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Foris V, Kovacs G, Tscherner M, Olschewski A and Olschewski H: Biomarkers in pulmonary hypertension: What do we know? Chest. 144:274–283. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ozanturk E, Ucar ZZ, Varol Y, Koca H, Demir AU, Kalenci D, Halilcolar H and Ozacar R: Urinary uric acid excretion as an indicator of severe hypoxia and mortality in patients with obstructive sleep apnea and chronic obstructive pulmonary disease. Rev Port Pneumol (2006). 22:18–26. 2016.PubMed/NCBI | |
|
Deng S, Zhu T, Wang C, Gu X, Zhang J, Lu Q, Yang Y and Ma X: Analysis of Correlation Between Serum Hypoxia-Inducible Factor-1α, Uric Acid, and Inflammatory Factor Levels and Lung Function in Patients with AECOPD. Altern Ther Health Med. AT8122:Aug 11–2023.(Epub ahead of print). PubMed/NCBI | |
|
Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, Stevenson JC and Coats AJ: Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 18:858–865. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Horodinschi RN, Bratu OG, Dediu GN, Pantea Stoian A, Motofei I and Diaconu CC: Heart failure and chronic obstructive pulmonary disease: A review. Acta Cardiol. 75:97–104. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, et al: Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 53:18019142019. View Article : Google Scholar : PubMed/NCBI | |
|
Kaufman M and Guglin M: Uric acid in heart failure: A biomarker or therapeutic target? Heart Fail Rev. 18:177–186. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Richette P, Frazier A and Bardin T: Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout. Curr Opin Rheumatol. 27:170–174. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Komori H, Yamada K and Tamai I: Hyperuricemia enhances intracellular urate accumulation via down-regulation of cell-surface BCRP/ABCG2 expression in vascular endothelial cells. Biochim Biophys Acta Biomembr. 1860:973–980. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yanai H, Adachi H, Hakoshima M and Katsuyama H: Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci. 22:92212021. View Article : Google Scholar : PubMed/NCBI | |
|
Lokmic Z, Musyoka J, Hewitson TD and Darby IA: Hypoxia and hypoxia signaling in tissue repair and fibrosis. Int Rev Cell Mol Biol. 296:139–185. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Alderman M and Aiyer KJ: Uric acid: Role in cardiovascular disease and effects of losartan. Curr Med Res Opin. 20:369–379. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Cai H and Harrison DG: Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res. 87:840–844. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Țăpoi L, Șalaru DL, Sascău R and Stătescu C: Uric Acid-An emergent risk marker for thrombosis? J Clin Med. 10:20622021. View Article : Google Scholar | |
|
Schober A: Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol. 28:1950–1959. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Voelkel NF, Mizuno S and Bogaard HJ: The role of hypoxia in pulmonary vascular diseases: A perspective. Am J Physiol Lung Cell Mol Physiol. 304:L457–L465. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Borghi C, Verardi FM, Pareo I, Bentivenga C and Cicero AF: Hyperuricemia and cardiovascular disease risk. Expert Rev Cardiovasc Ther. 12:1219–1225. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Das A, Kumar P, Kumari A, Chandra S, Gari M, Singh N and Dey D: Effects of cilnidipine on heart rate and uric acid metabolism in patients with essential hypertension. Cardiol Res. 7:167–172. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Qin X, Li Y, He M, Tang G, Yin D, Liang M, Wang B, Nie J, Huo Y, Xu X and Hou FF: Folic acid therapy reduces serum uric acid in hypertensive patients: A substudy of the China Stroke Primary Prevention Trial (CSPPT). Am J Clin Nutr. 105:882–889. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chida R, Hisauchi I, Toyoda S, Kikuchi M, Komatsu T, Hori Y, Nakahara S, Sakai Y, Inoue T and Taguchi I: Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients. Hypertens Res. 38:765–769. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kim EJ, Song WH, Lee JU, Shin MS, Lee S, Kim BO, Hong KS, Han SW, Park CG and Seo HS: Efficacy of losartan and carvedilol on central hemodynamics in hypertensives: a prospective, randomized, open, blinded end point, multicenter study. Hypertens Res. 37:50–56. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Newman CB: Safety of statins and nonstatins for treatment of dyslipidemia. Endocrinol Metab Clin North Am. 51:655–679. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Noori S, Mirzababaei A, Amini MR, Clark CCT and Mirzaei K: Effect of orlistat on serum uric acid level in adults: A systematic review and meta-analysis of randomised controlled trials. Int J Clin Pract. 75:e146742021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang G, Ma Y, Xi D, Rao Z, Sun X and Wu X: Effect of high uric acid on the disposition of metformin: in vivo and in vitro studies. Biopharm Drug Dispos. 40:3–11. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Katsiki N, Karagiannis A, Athyros VG and Mikhailidis DP: Hyperuricaemia: More than just a cause of gout. J Cardiovasc Med (Hagerstown). 14:397–402. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas MC: Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab. 5:53–61. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
George J, Carr E, Davies J, Belch JJ and Struthers A: High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 114:2508–2516. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Tani S, Nagao K and Hirayama A: Effect of febuxostat, a xanthine oxidase inhibitor, on cardiovascular risk in hyperuricemic patients with hypertension: A prospective, open-label, pilot study. Clin Drug Investig. 35:823–831. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lin HC, Daimon M, Wang CH, Ho Y, Uang YS, Chiang SJ and Wang LH: Allopurinol, benzbromarone and risk of coronary heart disease in gout patients: A population-based study. Int J Cardiol. 233:85–90. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SC, Neogi T, Kang EH, Liu J, Desai RJ, Zhang M and Solomon DH: Cardiovascular risks of probenecid versus allopurinol in older patients with gout. J Am Coll Cardiol. 71:994–1004. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Moss JD, Wu M, Axelrod DM and Kwiatkowski DM: Rasburicase versus intravenous allopurinol for non-malignancy-associated acute hyperuricemia in paediatric cardiology patients. Cardiol Young. 29:1160–1164. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vázquez-Mellado J, White WB, Lipsky PE, Horowitz Z, et al: Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA. 306:711–720. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Theilmann AL and Ormiston ML: Repurposing benzbromarone for pulmonary arterial hypertension: Can channelling the past deliver the therapy of the future? Eur Respir J. 53:19005832019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu-Shiu-Cheong PSK, Lipworth BJ, Weir-McCall JR, Houston JG and Struthers AD: Allopurinol in patients with pulmonary hypertension associated with chronic lung disease. Int J Chron Obstruct Pulmon Dis. 15:2015–2024. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gokcen T, Inci K, Inci EE, Sevgen O and Serdar U: Allopurinol treatment reduced vascular remodeling and improved vascular functions in monocrotaline-induced pulmonary hypertensive rats. Pulm Pharmacol Ther. 77:1021662022. View Article : Google Scholar : PubMed/NCBI | |
|
De Scheerder IK, van de Kraay AM, Lamers JM, Koster JF, de Jong JW and Serruys PW: Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: Potential mechanisms for free radical generation. Am J Cardiol. 68:392–395. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Friedl HP, Till GO, Trentz O and Ward PA: Role of oxygen radicals in tourniquet-related ischemia-reperfusion injury of human patients. Klin Wochenschr. 69:1109–1112. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Many A, Hubel CA and Roberts JM: Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Am J Obstet Gynecol. 174((1 Pt 1)): 288–291. 1996. View Article : Google Scholar : PubMed/NCBI |
